Abstract |
In this study, a novel SEC2 mutant with lower toxic activity, named 2M-118 (H118A/T20L/G22E), was engineered by site-directed mutagenesis of structural domains that are responsible for MHC class II molecule binding and TCR binding, respectively. Stimulating activity on murine splenocytes, anti- tumor effect and immunogenicity of 2M-118 were investigated in BALB/c mice. 2M-118 not only remained splenocyte stimulation activity, but also effectively inhibited the growth of S180 sarcoma in the BALB/c mice. Even though antibodies to 2M-118 could be induced after repeated administration, the action of 2M-118 was hardly neutralized or cross neutralized. Like other superantigens, immunosuppression could happen when 2M-118 was given at a greater dose. In conclusion, 2M-118 is a promising anti- tumor drug candidate for its acceptable toxicity and satisfying anti-tumour efficacy.
|
Authors | J Zhang, Y M Cai, M K Xu, Z H Song, C Y Li, H R Wang, H H Dai, Z P Zhang, C X Liu |
Journal | Die Pharmazie
(Pharmazie)
Vol. 68
Issue 5
Pg. 359-64
(May 2013)
ISSN: 0031-7144 [Print] Germany |
PMID | 23802434
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents
- Enterotoxins
- Receptors, Antigen, T-Cell
- enterotoxin C, staphylococcal
|
Topics |
- Animals
- Antineoplastic Agents
- Cell Line, Tumor
- Cell Proliferation
(drug effects)
- Enterotoxins
(immunology, pharmacology, toxicity)
- Enzyme-Linked Immunosorbent Assay
- Genes, MHC Class II
(genetics)
- Humans
- Lymphocytes
(drug effects)
- Mice
- Mice, Inbred BALB C
- Mutagenesis, Site-Directed
- Plasmids
(genetics)
- Receptors, Antigen, T-Cell
(drug effects, metabolism)
- Spleen
(cytology, drug effects)
- Staphylococcus aureus
(chemistry, genetics)
|